Skip to main content
Journal ArticleOPEN ACCESS

Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan

Journal of Clinical Hypertension (2015) 17(1) 51-58
DOI: 10.1111/jch.12449
28Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This retrospective claims database analysis compared two strategies of hypertension treatment in outpatient, emergency, and inpatient departments: a fixed-dose combination (FDC) of amlodipine/valsartan vs free combinations of angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) (ARB+CCB group). After a mean follow-up of 15.2 months, the FDC group had significantly lower total healthcare costs (US $1844 vs US $2158; P

Cite

CITATION STYLE

APA

Tung, Y. C., Lin, Y. S., Wu, L. S., Chang, C. J., & Chu, P. H. (2015). Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. Journal of Clinical Hypertension, 17(1), 51–58. https://doi.org/10.1111/jch.12449

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free